Urovant Sciences Ltd (UROV) Receives Consensus Rating of “Buy” from Brokerages

Shares of Urovant Sciences Ltd (NASDAQ:UROV) have earned a consensus recommendation of “Buy” from the six research firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $23.40.

UROV has been the subject of a number of research analyst reports. HC Wainwright initiated coverage on shares of Urovant Sciences in a research report on Monday, March 11th. They issued a “buy” rating and a $28.00 target price for the company. SunTrust Banks initiated coverage on shares of Urovant Sciences in a research report on Friday, March 15th. They issued a “buy” rating and a $24.00 target price for the company. Finally, Zacks Investment Research downgraded shares of Urovant Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, December 26th.

A number of large investors have recently bought and sold shares of the business. FMR LLC grew its position in Urovant Sciences by 11.1% in the 4th quarter. FMR LLC now owns 1,332,701 shares of the company’s stock worth $8,782,000 after purchasing an additional 132,701 shares during the period. Perceptive Advisors LLC grew its position in shares of Urovant Sciences by 35.2% during the 4th quarter. Perceptive Advisors LLC now owns 625,359 shares of the company’s stock valued at $3,915,000 after acquiring an additional 162,700 shares during the period. Sio Capital Management LLC bought a new stake in shares of Urovant Sciences during the 3rd quarter valued at $7,097,000. BlackRock Inc. bought a new stake in shares of Urovant Sciences during the 3rd quarter valued at $4,574,000. Finally, Sphera Funds Management LTD. grew its position in shares of Urovant Sciences by 30.5% during the 4th quarter. Sphera Funds Management LTD. now owns 214,030 shares of the company’s stock valued at $1,410,000 after acquiring an additional 50,000 shares during the period. 22.77% of the stock is owned by institutional investors and hedge funds.

NASDAQ UROV traded down $0.73 during mid-day trading on Tuesday, reaching $8.75. The stock had a trading volume of 26,183 shares, compared to its average volume of 109,689. Urovant Sciences has a 1 year low of $4.05 and a 1 year high of $14.49.

Urovant Sciences (NASDAQ:UROV) last announced its quarterly earnings data on Wednesday, February 13th. The company reported ($0.87) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.22. Sell-side analysts expect that Urovant Sciences will post -3.96 earnings per share for the current fiscal year.

About Urovant Sciences

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.

Further Reading: Market Capitalization – What it Means for Investors

Analyst Recommendations for Urovant Sciences (NASDAQ:UROV)

Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit